General Information of Drug (ID: DMTDRPM)

Drug Name
impromidine Drug Info
Synonyms SK&F-92676-A3
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
41376
CAS Number
CAS 55273-05-7
TTD Drug ID
DMTDRPM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug(s) Targeting Histamine H4 receptor (H4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-3893787 DMC2FAL Atopic dermatitis EA80 Phase 2 [5]
JNJ-38518168 DM9UMIO Plaque psoriasis EA90.0 Phase 2 [6]
UR-63325 DME6X27 Allergic rhinitis CA08.0 Phase 2 [7]
Thioperamide DM8S593 Cognitive impairment 6D71 Terminated [8]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG Discovery agent N.A. Investigative [9]
burimamide DMZ2VYG Discovery agent N.A. Investigative [10]
Imetit DMMJ6NS Discovery agent N.A. Investigative [11]
[125I]iodophenpropit DMN4ABU Discovery agent N.A. Investigative [12]
(R)-alpha-methylhistamine DMKAW4P Discovery agent N.A. Investigative [3]
N-[3H]alpha-methylhistamine DMWDCV1 Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H2 receptor (H2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [14]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [15]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [15]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [16]
Betazole DMUFGAY Gastric secretory disorder DD90 Approved [17]
Ebrotidine DMV5KR3 Duodenal ulcer DA63 Withdrawn from market [18]
Pibutidine DMXSTRM Ulcerative colitis DD71 Discontinued in Phase 3 [19]
Osutidine DMN7TL8 Duodenal ulcer DA63 Discontinued in Phase 3 [20]
KU-1257 DMZMFX6 Duodenal ulcer DA63 Discontinued in Phase 3 [21]
Lavoltidine DMTY5VE Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H3 receptor (H3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pitolisant DM8RFNJ Excessive daytime sleepiness MG42 Approved [23]
SUVN-G3031 DM3BO8G Cognitive impairment 6D71 Phase 3 [24]
JNJ-17216498 DM1GRCU Narcolepsy 7A20 Phase 2 [25]
GSK239512 DMBJMZC Alzheimer disease 8A20 Phase 2 [26]
JNJ-39220675 DM0WY3H Alcohol dependence 6C40.2 Phase 2 [27]
AZD-5213 DMOZ04X Alzheimer disease 8A20 Phase 2 [28]
Bavisant DM6CVZ5 Attention deficit hyperactivity disorder 6A05.Z Phase 2 [29]
ABT-288 DM7X54F Alzheimer disease 8A20 Phase 2 [30]
SAR-110894 DMCLEXM Alzheimer disease 8A20 Phase 2 [28]
ABT-652 DMLEO2Z Diabetic neuropathy 8C0Z Phase 2 [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histamine H1 receptor (H1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [3]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [32]
Azelastine DMXTMBJ Allergic conjunctivitis 9A60.02 Approved [33]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [34]
Cinnarizine DM7U5QJ Meniere disease AB31.0 Approved [35]
Diphenhydramine DMKQTBA Hyperemesis gravidarum Approved [33]
Doxepin DMPI98T Anxiety Approved [36]
Chlorpheniramine DM5URA2 Allergic rhinitis CA08.0 Approved [33]
Epinastine DMX0K3Q Allergic conjunctivitis 9A60.02 Approved [37]
Desloratadine DM56YN7 Allergic rhinitis CA08.0 Approved [38]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [2]
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Agonist [2]
Histamine H3 receptor (H3R) TT9JNIC HRH3_HUMAN Agonist [3]
Histamine H4 receptor (H4R) TTXJ178 HRH4_HUMAN Agonist [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1226).
2 Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46.
3 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
4 Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21.
5 Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602.
6 The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65.
7 Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87.
8 Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain. J Neurochem. 2008 Nov;107(4):976-86.
9 Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8.
10 Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30.
11 Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol. 2006 Apr;95(4):2492-500.
12 Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008 Jun 12;51(11):3145-53.
13 Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor. Br J Pharmacol. 2003 Nov;140(6):1117-27.
14 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
15 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
16 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
17 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
18 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
19 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
20 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
21 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
22 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
23 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
26 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
27 JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
28 SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
29 Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
30 A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
32 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
33 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
34 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
35 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
36 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
37 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
38 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.